Brief: Selecta Biosciences Completed Enrollment In Dissolve Ii Phase 3 Clinical Trial Of SEL-212 For Treatment Of Chronic Refractory Gout

Cartesian Therapeutics

30/06/2022 13:20

June 30 (Reuters) - Selecta Biosciences Inc  SELB.O :
    * SELECTA BIOSCIENCES -  ON JUNE 29, CO COMPLETED ENROLLMENT
IN
DISSOLVE II PHASE 3 CLINICAL TRIAL OF SEL-212 FOR TREATMENT OF
CHRONIC REFRACTORY GOUT
    * SELECTA BIOSCIENCES INC -  EXPECTS TO ANNOUNCE TOP-LINE
RESULTS
FROM DISSOLVE II PHASE 3 CLINICAL TRIAL IN FIRST QUARTER OF 2023

Further company coverage:  SELB.O